¼¼°èÀÇ ½ÃÅä½Å ½ÃÀå
Cytosine
»óǰÄÚµå : 1791610
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 186 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License)
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)


Çѱ۸ñÂ÷

¼¼°èÀÇ ½ÃÅä½Å ½ÃÀåÀº 2030³â±îÁö 5¾ï 9,530¸¸ ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 3¾ï 6,260¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ½ÃÅä½Å ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 8.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 5¾ï 9,530¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÀǾàǰ ÃÖÁ¾ »ç¿ëÀº CAGR 9.8%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 3¾ï 130¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ³ó¾÷¿ë ÃÖÁ¾ »ç¿ë ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 8.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 9,880¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 13.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½ÃÅä½Å ½ÃÀåÀº 2024³â¿¡ 9,880¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 1¾ï 3,070¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 13.6%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 4.3%¿Í 8.3%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.8%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ½ÃÅä½Å ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ Á¤¸®

½ÃÅä½ÅÀº ¿Ö »ý¸í°øÇÐ ¹× Á¦¾à ºÐ¾ß¿¡¼­ Á¡Á¡ ´õ Áß¿äÇØÁö°í Àִ°¡?

½ÃÅä½ÅÀº Áú¼Ò ¿°±âÀ̸ç DNA¿Í RNAÀÇ Çʼö ¼ººÐÀ¸·Î À¯ÀüÀÚ ¿¬±¸, ÀǾàǰ °³¹ß, »ý¸í°øÇÐ ÀÀ¿ë¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Ç×¹ÙÀÌ·¯½ºÁ¦ ¹× Ç×¾ÏÁ¦ Á¦Á¶¿¡ »ç¿ëµÇ´Â ´ºÅ¬·¹¿À½Ãµå ¾Æ³¯·Î±×ÀÇ ÁÖ¿ä Àü±¸Ã¼ ¿ªÇÒÀ» ÇÕ´Ï´Ù. À¯ÀüÀÚ Ä¡·á, ¸ÂÃãÀÇ·á, ºÐÀÚÁø´Ü¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ÀǾàǰ °³¹ß ¹× À¯Àü°øÇÐ ºÐ¾ß¿¡¼­ ½ÃÅä½Å ±â¹Ý È­ÇÕ¹°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÇÕ¼º»ý¹°Çаú CRISPR ±â¹Ý À¯ÀüÀÚ ÆíÁýÀÇ ºÎ»óÀº ½ÃÅä½ÅÀÇ ¿ëµµ¸¦ ´õ¿í È®´ëÇß½À´Ï´Ù. °úÇÐÀÚµéÀº ½ÃÅä½ÅÀÇ º¯ÇüÀ» Ȱ¿ëÇÏ¿© À¯ÀüÁúȯ, ÀÚ°¡¸é¿ªÁúȯ, Ç¥Àû ¾Ï Ä¡·á¸¦ À§ÇÑ Ã·´Ü Ä¡·áÁ¦¸¦ °³¹ßÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÃÅä½Å À¯µµÃ¼´Â »õ·Î¿î RNA ±â¹Ý ¹é½ÅÀ» À§ÇØ ¿¬±¸µÇ°í ÀÖÀ¸¸ç, ¹é½Å ±â¼úÀÇ ¹ßÀü¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

½ÃÅä½Å ¿¬±¸ÀÇ Ãֽбâ¼ú ¹ßÀüÀº ¹«¾ùÀΰ¡?

½ÃÅä½Å °ü·Ã ¿¬±¸¿¡¼­ °¡Àå Áß¿äÇÑ ÁøÀü Áß Çϳª´Â CRISPR-Cas9°ú ¿°±â±³Á¤ ±â¼úÀÇ °³¹ßÀÔ´Ï´Ù. ½ÃÅä½Å ¿°±âÆíÁý±â(CBE)´Â ½ÃÅä½ÅÀ» Ƽ¹ÎÀ¸·Î º¯È¯ÇÏ¿© Á¤È®ÇÑ À¯ÀüÀÚ º¯ÇüÀ» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á À¯ÀüÀÚ º¯À̸¦ ±³Á¤Çϴ ȹ±âÀûÀÎ Á¢±Ù¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº À¯Àü ÀÇÇп¡ Çõ¸íÀ» °¡Á®¿Ô°í, À¯Àü¼º Áúȯ°ú Èñ±Í À¯Àü ÁúȯÀ» ´ë»óÀ¸·Î ÇÑ Ä¡·á¹ýÀÇ ±æÀ» ¿­¾ú½À´Ï´Ù.

¶Ç ´Ù¸¥ ÁÖ¿ä ¹ßÀüÀº Ç×¹ÙÀÌ·¯½º ¹× ¸é¿ª ¿ä¹ý¿¡ Àû¿ëÇϱâ À§ÇÑ ½ÃÅä½Å À¯»çüÀÇ ÇÕ¼ºÀÔ´Ï´Ù. Á¦¾à ¿¬±¸ÀÚµéÀº ¾à¹°ÀÇ ¾ÈÁ¤¼º, »ýü ÀÌ¿ë·ü, ¾àÁ¦ ³»¼º ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ È¿´ÉÀ» ³ôÀ̱â À§ÇØ º¯ÇüµÈ ½ÃÅä½Å ºÐÀÚ¸¦ °øÇÐÀûÀ¸·Î ¿¬±¸Çϰí ÀÖ½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ ½Å¾à°³¹ß Ç÷§Æûµµ ½ÃÅä½Å ±â¹Ý È­ÇÕ¹° ½ºÅ©¸®´×À» °¡¼ÓÈ­ÇÏ¿© Â÷¼¼´ë ´ºÅ¬·¹¿À½Ãµå Ä¡·áÁ¦ °³¹ßÀ» È¿À²È­Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå µ¿Çâ°ú ±ÔÁ¦ ÁöħÀÌ ½ÃÅä½Å äÅÿ¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

½ÃÀå µ¿ÇâÀº ÇÙ»ê ±â¹Ý Ä¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ °í¼øµµ ½ÃÅä½Å À¯µµÃ¼¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. RNA Ä¡·áÁ¦ÀÇ ±Þ¼ÓÇÑ ¹ßÀü, ƯÈ÷ mRNA ¹é½ÅÀÇ ¼º°øÀº »ý¹° ÀÇÇÐ Çõ½Å¿¡¼­ ½ÃÅä½ÅÀÇ ¿ªÇÒÀ» ´õ¿í ºÎ°¢½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯ÀüÀÚ ¿¬±¸ ¹× Á¤¹ÐÀÇ·á ÀÌ´Ï¼ÅÆ¼ºê¿¡ ´ëÇÑ ÀÚ±Ý Áö¿øÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀǾàǰ ¿¬±¸ ¹× °³¹ß¿¡ ½ÃÅä½Å ±â¹Ý ±â¼úÀÇ Ã¤ÅÃÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

¹Ì±¹ FDA¿Í À¯·´ÀǾàǰû(EMA) µî ±ÔÁ¦±â°üÀº ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇϱâ À§ÇØ ÇÙ»ê ±â¹Ý Ä¡·á¹ýÀ» ¾ö°ÝÇÏ°Ô ¸ð´ÏÅ͸µÇϰí ÀÖ½À´Ï´Ù. ¾ö°ÝÇÑ Ç°Áú °ü¸®¿Í GMP(Good Manufacturing Practice) °¡À̵å¶óÀÎ Áؼö´Â ½ÃÅä½Å Á¦Á¶¾÷üµéÀÌ °í¼øµµ Á¦Á¶ °øÁ¤¿¡ ÅõÀÚÇϵµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯ÀüÀÚ ÆíÁý°ú ÇÕ¼º»ý¹°ÇÐÀ» µÑ·¯½Ñ À±¸®Àû °í·Á°¡ ±ÔÁ¦ »óȲÀ» Çü¼ºÇÏ°í ½ÃÀå °³Ã´¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

½ÃÅä½Å ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº?

½ÃÅä½Å ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº À¯ÀüÀÚ Ä¡·á, ºÐÀÚÁø´Ü, Ç×¹ÙÀÌ·¯½ºÁ¦ °³¹ß ºÐ¾ßÀÇ È®´ëÀÔ´Ï´Ù. À¯Àü¼º Áúȯ°ú °¨¿°¼º ÁúȯÀÇ È®»êÀÌ Áõ°¡ÇÔ¿¡ µû¶ó, ƯÈ÷ Á¾¾çÇÐ ¹× ¹ÙÀÌ·¯½ºÇÐ ºÐ¾ß¿¡¼­ ½ÃÅä½Å ±â¹Ý Ä¡·áÁ¦¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÃÖÁ¾ ¿ëµµÀÇ È®´ëµµ Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀ̸ç, ½ÃÅä½ÅÀº »ý¸í°øÇÐ ¿¬±¸, ¹ýÀÇÇÐ, ³ó¾÷À¯ÀüüÇп¡ ³Î¸® Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. DNA ±â¹Ý µ¥ÀÌÅÍ ÀúÀå ±â¼úÀÇ ÃâÇöµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ¿¬±¸ÀÚµéÀº °í¹Ðµµ Á¤º¸ ÀúÀå¿¡ ´ëÇÑ ½ÃÅä½ÅÀÇ °¡´É¼ºÀ» ޱ¸Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ý¸í°øÇÐ ±â¾÷, Á¦¾àȸ»ç, Çмú±â°üÀÇ Çù¾÷À¸·Î ½ÃÅä½Å °ü·Ã ½Å¾à°³¹ß°ú À¯Àü°øÇÐÀÇ Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. À¯ÀüüÇÐ ¹× Á¤¹ÐÀÇ·áÀÇ ¹ßÀü°ú ÇÔ²² ½ÃÅä½Å ½ÃÀåÀº Áö¼ÓÀûÀÎ ¼ºÀå¼¼¸¦ º¸À̸ç À¯ÀüÀÚ ¿¬±¸ ¹× Ä¡·áÁ¦ °³¹ßÀÇ ¹Ì·¡¸¦ Çü¼ºÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

ÃÖÁ¾»ç¿ëÀÚ(ÀǾàǰ ÃÖÁ¾»ç¿ëÀÚ, ³ó¾÷ ÃÖÁ¾»ç¿ëÀÚ, È­ÇÐ »ê¾÷ ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå°ú °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Cytosine Market to Reach US$595.3 Million by 2030

The global market for Cytosine estimated at US$362.6 Million in the year 2024, is expected to reach US$595.3 Million by 2030, growing at a CAGR of 8.6% over the analysis period 2024-2030. Pharmaceutical End-Use, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$301.3 Million by the end of the analysis period. Growth in the Agriculture End-Use segment is estimated at 8.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$98.8 Million While China is Forecast to Grow at 13.6% CAGR

The Cytosine market in the U.S. is estimated at US$98.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$130.7 Million by the year 2030 trailing a CAGR of 13.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.3% and 8.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Global Cytosine Market - Key Trends & Growth Drivers Summarized

Why Is Cytosine Gaining Significance in Biotechnology and Pharmaceuticals?

Cytosine, a nitrogenous base and an essential component of DNA and RNA, plays a vital role in genetic research, pharmaceutical development, and biotechnology applications. It serves as a key precursor in nucleoside analogs used for antiviral and anticancer drug formulations. The increasing focus on gene therapy, personalized medicine, and molecular diagnostics has elevated the demand for cytosine-based compounds in drug development and genetic engineering.

The rise of synthetic biology and CRISPR-based genome editing has further expanded cytosine’s applications. Scientists are leveraging cytosine modifications to develop advanced therapeutics for genetic disorders, autoimmune diseases, and targeted cancer treatments. Additionally, cytosine derivatives are being explored for novel RNA-based vaccines, contributing to advancements in vaccine technology.

What Are the Latest Technological Advancements in Cytosine Research?

One of the most significant advancements in cytosine-related research is the development of CRISPR-Cas9 and base editing technologies. Cytosine base editors (CBEs) enable precise genetic modifications by converting cytosine to thymine, offering a groundbreaking approach to correcting genetic mutations. These innovations have revolutionized genetic medicine, paving the way for therapies targeting inherited diseases and rare genetic disorders.

Another key development is the synthesis of cytosine analogs for antiviral and immunotherapy applications. Pharmaceutical researchers are engineering modified cytosine molecules to enhance drug stability, bioavailability, and efficacy against drug-resistant viruses. AI-driven drug discovery platforms are also accelerating cytosine-based compound screening, streamlining the development of next-generation nucleoside therapeutics.

How Are Market Trends and Regulatory Guidelines Influencing Cytosine Adoption?

Market trends indicate a growing interest in nucleic acid-based therapies, driving the demand for high-purity cytosine derivatives. The rapid advancements in RNA therapeutics, particularly with the success of mRNA vaccines, have further highlighted cytosine’s role in biomedical innovation. Additionally, increased funding for genetic research and precision medicine initiatives is accelerating the adoption of cytosine-based technologies in pharmaceutical R&D.

Regulatory agencies, including the U.S. FDA and the European Medicines Agency (EMA), are closely monitoring nucleic acid-based therapies to ensure safety and efficacy. Compliance with stringent quality control and Good Manufacturing Practice (GMP) guidelines has encouraged cytosine manufacturers to invest in high-purity production processes. Additionally, ethical considerations surrounding gene editing and synthetic biology are shaping the regulatory landscape, influencing market development.

What Is Driving the Growth of the Cytosine Market?

The growth in the cytosine market is driven by the expanding fields of gene therapy, molecular diagnostics, and antiviral drug development. The increasing prevalence of genetic diseases and infectious disorders has fueled the need for cytosine-based therapeutics, particularly in oncology and virology.

End-use expansion is another critical factor, with cytosine being widely utilized in biotechnology research, forensic science, and agricultural genomics. The emergence of DNA-based data storage technologies is also contributing to market expansion, as researchers explore cytosine’s potential in high-density information storage. Additionally, collaborations between biotech firms, pharmaceutical companies, and academic institutions are fostering innovation in cytosine-related drug discovery and genetic engineering. As advancements in genomics and precision medicine continue, the cytosine market is expected to experience sustained growth, shaping the future of genetic research and therapeutic development.

SCOPE OF STUDY:

The report analyzes the Cytosine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

End-Use (Pharmaceutical End-Use, Agriculture End-Use, Chemical Industry End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â